Value-based payment for oncology services in the United States and France

详细信息    查看全文

• 作者：James C. Robinson^a ; ^{James.Robinson@berkeley.edu} (Leonard D. Schaeffer Professor of Health Economics) ; Francis Megerlin^b ; ^{francis.megerlin@icloud.com} (Professor of Law ; Health Policy)
• 关键词：Cancer ; Oncology ; Value ; Payment reform ; Medical home
• 刊名：Journal of Cancer Policy
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：11
• 期：Complete
• 页码：38-41
• 全文大小：264 K
• 卷排序：11

文摘

High-value medical oncology requires that chemotherapies and biologics be administered to the right patient, at the right time, in the right dose, and in combination with the right supportive medications. Rather than being the domain of startup and established biopharmaceutical firms, innovation in methods of use occurs at the level of the physician and the hospital. Oncology payment mechanisms vary across nations but the challenges of appropriate drug selection and patient engagement are common to all. Value-based drug pricing goes beyond the amounts reimbursed for the drugs themselves to encompass the methods used to reimburse the physicians that prescribe, deliver, monitor, and manage those drugs.